drugset / Trial / NCT07226349

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349

Phase 1 Recruiting 105 enrolled BeOne Medicines
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Timeline

Start
2025-12-11
Primary completion
2028-11-01
Completion
2028-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BG-75098 Unknown Oral
Subject BGB-43395 Unknown Oral
Subject Fulvestrant Small molecule Intramuscular

Indications